Search

Your search keyword '"Brown-Frandsen, Kirstine"' showing total 23 results

Search Constraints

Start Over You searched for: Author "Brown-Frandsen, Kirstine" Remove constraint Author: "Brown-Frandsen, Kirstine"
23 results on '"Brown-Frandsen, Kirstine"'

Search Results

1. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

2. #2496 Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial

3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

4. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL , a randomized trial, design and baseline characteristics

7. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.

8. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.

9. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design

10. Rates of Major Adverse Cardiovascular Events and Mortality with Basal Insulin by Liraglutide Use: A DEVOTE Subanalysis

11. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

12. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

13. Liraglutide and Renal Outcomes in Type 2 Diabetes

14. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

15. Étude LEADER : liraglutide et évolution de la fonction rénale dans le diabète de type 2

16. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10).

18. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.

19. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).

21. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)

22. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

23. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Catalog

Books, media, physical & digital resources